AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
AstraZeneca Reaffirmed as Buy by UBS, Target at £14,200
ByAinvest
Tuesday, Aug 5, 2025 5:24 am ET1min read
UBS reaffirms Buy rating on AstraZeneca with a p14,200.00 price target. Analyst Matthew Weston has a 4-star rating and a 64.10% success rate. The current analyst consensus is a Strong Buy with an average price target of p13,531.92, a 20.61% upside from current levels.
UBS has reaffirmed its Buy rating on AstraZeneca (NASDAQ: AZN) with a price target of $142.00, as announced by analyst Matthew Weston. Weston, who has a 4-star rating and a 64.10% success rate, believes that the stock offers significant upside potential. The current analyst consensus is a Strong Buy, with an average price target of $135.31.92, indicating a 20.61% upside from current levels.AstraZeneca reported earnings of $1.09 per share for the quarter, meeting analysts' expectations and surpassing revenue estimates of $14.08 billion. The company's net margin stood at 14.14%, with a year-over-year revenue increase of 16.1%. AstraZeneca also announced a semi-annual dividend of $0.505, reflecting a yield of 2% and a payout ratio of 82.73% [1].
The stock has seen increased interest from institutional investors, with 594 adding shares to their portfolios in the most recent quarter, compared to 522 decreasing their positions. Notable recent moves include Fisher Asset Management, LLC adding 9.2 million shares and Bank of America Corp /DE/ adding 7.8 million shares in the first quarter of 2025 [2].
Analysts have also been bullish on AstraZeneca, with 1 firm issuing a Buy rating and none issuing a Sell rating. UBS's Weston has a 4-star rating and a 64.10% success rate, indicating a strong track record. The current analyst consensus is a Strong Buy, with an average price target of $135.31.92, suggesting a 20.61% upside from current levels [2].
While AstraZeneca has shown strong financial performance and has received positive analyst ratings, investors should remain vigilant about potential risks, such as pricing challenges and trade uncertainties. The company's recent earnings report and analyst ratings provide a positive outlook for AstraZeneca's stock, but investors should conduct their own due diligence before making investment decisions.
References:
[1] https://www.marketbeat.com/instant-alerts/astrazeneca-nasdaqazn-announces-quarterly-earnings-results-hits-expectations-2025-07-30/
[2] https://www.quiverquant.com/news/AstraZeneca+Stock+%28AZN%29+Opinions+on+Record+Quarterly+Earnings
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet